Edifas B
CAS 9004-32-4
Edifas B (CAS 9004-32-4) is a pharmaceutical compound with 0 bioactivity targets and 1,548 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Cross-Reference to Chemicals
Same-CAS substance identity is available in the industrial chemicals vertical.
Edifas B is linked to DTXSID2020555 in DSSTox identifiers.
View industrial chemical data →Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Edifas B used for in pharmaceutical contexts?
Edifas B (CAS 9004-32-4) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Edifas B?
Edifas B has 1,548 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Abdominal pain, Abdominal pain upper, Abnormal faeces, Abnormal sensation in eye, Alopecia. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Edifas B also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Sodium Carboxymethyl Cellulose with EU status "permitted".
What clinical phase is Edifas B in?
No phase 1-4 clinical development badge is rendered for Edifas B because the matched compound identifier rows do not contain a max-phase value.